Nephros (NEPH) Cash & Equivalents (2010 - 2026)

Nephros' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 1.54% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (down 1.54% YoY), while the FY2025 annual figure was $5.4 million, up 43.62% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $4.0 million, down from $5.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $5.4 million in Q1 2022, with the low at $2.5 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $4.1 million (2023), against an average of $4.2 million.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents tumbled 49.52% in 2022, then surged 110.46% in 2025.
• Nephros' Cash & Equivalents stood at $3.6 million in 2022, then rose by 18.52% to $4.3 million in 2023, then slipped by 12.7% to $3.8 million in 2024, then surged by 43.62% to $5.4 million in 2025, then slipped by 25.59% to $4.0 million in 2026.
• Business Quant data shows NEPH's Cash & Equivalents at $4.0 million in Q1 2026, $5.4 million in Q4 2025, and $5.2 million in Q3 2025.